Basis of Presentation and Significant Accounting Policies - Narrative (Details)	1 Months Ended						3 Months Ended		12 Months Ended		82 Months Ended
	Mar. 31, 2023 USD ($) shares	Jan. 31, 2020 shares	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2023 USD ($) segment shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2017 USD ($)	Mar. 31, 2023 USD ($) shares	Oct. 31, 2018	Sep. 30, 2018
Goodwill	$ (3,301,959)						$ (3,301,959)		$ (3,301,959)		$ (3,301,959)
Accumulated deficit	221,938,306						221,938,306		209,153,659		221,938,306
Net loss							12,895,136	$ 8,189,798
Cash, cash equivalents and short term investments	28,600,000						28,600,000				28,600,000
Derivative warrant liability	0						$ 0				0
Number of operating segments | segment							1
Other assets	$ 5,557,073						$ 5,557,073		$ 260,011		$ 5,557,073
Warrants outstanding | shares	9,357						9,357				9,357
Revenue							$ 765,900	212,418
Customer deposits	$ 2,000,000.0						$ 2,000,000.0				$ 2,000,000.0
Shattuck
License fee received						$ 50,000
Initial license fees received						50,000
Proceeds from milestone payment	$ 100,000
Minimum
Estimated useful lives							3 years
Maximum
Estimated useful lives							8 years
Warrant
Number of warrants reclassified to liability | shares		479,595
Pelican Therapeutics, Inc.
Ownership interest in subsidiary	85.00%						85.00%		85.00%		85.00%	85.00%	80.00%
Pelican Therapeutics, Inc.
Contingent consideration liability, written off									$ 3,300,000
Pelican Therapeutics, Inc. | In-process R&D.
Acquired finite-lived intangible assets										$ (5,900,000)
Pelican Therapeutics, Inc. | Grant and contract revenue
Revenue							$ 0	$ 200,000			$ 15,200,000
Remaining grant amount receivable	$ 1,500,000						$ 1,500,000				$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue					$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue				$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue			$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant						$ 15,200,000